Place: Actelion, Gewerbestrasse 12, 4123 Allschwil
Place: Actelion, Gewerbestrasse 12, 4123 Allschwil
When building a life sciences company, investments and partnerships are going to be a key element to success. In today's ever-changing regulatory and financing environment, it is becoming increasingly important to engage early in the process. How can you adapt your business strategy to ensure you are setting your company up for fruitful partnerships? How are investors adapting their financing strategies and business models to accommodate new realities and positioning themselves for long-term success? Join a panel of biotech and life sciences investors and business development professionals as they discuss their approaches to partnering.
Who should attend
This event is geared towards business development professionals and management teams of life science companies.
When: 21.03.2019, 16:30 - 18:00
Where: Actelion, Gewerbestrasse 12, 4123 Allschwil
Welcome & Registration
Guenther Huhle, Head of JLABS EMEA, Johnson & Johnson Innovation
Markus Werner, VP Partnering of Molecular Partners
Participation to the event is free of charge; however, your registration is mandatory.
Prior to joining JLABS, Guenter was leading the Business Development Organization and the Mature Brands at Janssen – the pharmaceutical companies of Johnson & Johnson in EMEA - Europe Middle East and Africa incl. Russia and CIS. Guenter received his MD and PhD from the University of Heidelberg and his Master of Science from the University of Witten/Herdecke. He is board accredited in Internal Medicine and Haemostaseology and owns a Professorship at the University of Heidelberg. Since he moved into the pharmaceutical Industry in 2001, Guenter has held various national, regional and global Leadership positions in R&D, Medical and the Business, first at Eli Lilly and then at Merck KGaA until joining Janssen and Johnson & Johnson in 2007. Guenter is experienced in Business modeling, Licensing, Merger & Acquisitions, Science, Medical and Market access in Healthcare. He privately supports start-up businesses as investor and entrepreneur and has founded Corevas® in 2015. Corevas® is a privately owned limited liability company developing EmergencyEye®, a potentially life-saving communication technology innovation for emergency case management with an estimated launch date for Q4/2018.
Carole has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals. She currently serves as a director at Aligos Therapeutics, Arch Oncology, CiVi, Maculogix, Millendo, Mission Therapeutics, Lumos, Lysosomal Therapeutics, Inc, Second Genome and Vivet. She was formerly a director at Allakos and AveXis. She also led the investments on Alios, Ambit, Ambrx, Conatus, Envoy, Nereus and Pharmasset. She has a BA from Valparaiso University and a JD from University of Michigan.
Dominik was a founder of ESBATech and led the company as CEO from its inception in 1998 until 2016. In 2009, with the acquisition of ESBATech by Alcon, Dominik became the Vice President of R&D Alcon and member of the group’s Global R&D Leadership Team. In 2011, when Alcon was acquired by Novartis, ESBATech joined the Novartis Institutes of Biomedical Research (NIBR). As Head of ESBATech, now a Novartis company, Dominik was a member of the NIBR Global Ophthalmology Leadership Team as well as the NIBR Global Leadership Team of Biologics. In 2017, Dominik co-founded CDR-Life and became the Executive Chairman of the company. He also co-launched the venture fund Pureos Bioventures currently raising CHF 200 million to invest exclusively in private innovative drug development companies, with a special emphasis on next generation of biological drugs. Dominik obtained his Ph.D. and a Master of Science in Molecular Biology and Immunology both from the University of Zurich. He also holds a Masters in Education with specialization in Management and Organization from the ETH of Zurich. Since 2002 he is a Board Member of the Swiss Biotech Association, which he leads as President since 2013.
Sascha is Roivant Pharma’s Head of Basel and Head of Global Transactions. Prior to joining Roivant two years ago, Sascha worked for Roche in numerous Business and Corporate Development functions including as Deputy Head of Global M&A where he was involved in 100+ transactions and negotiated and closed over 35 international deals. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel, and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager.
Markus is VP Partnering of Molecular Partners and leads the business development team in selecting new partners, negotiating collaboration agreements, managing existing partnerships and providing commercial expertise and input for all corporate pipeline activities. Markus brings a scientific background in molecular bioengineering and more than 18 years of experience in pharmaceutical collaborations and partnerships. Prior to his role at Molecular Partners, Markus has held various business development positions in biotech and pharma, most recently at BioNTech AG, Takeda, Nycomed and Altana Pharma. His deal track record covers the pharmaceutical value chain from early drug discovery to commercial-stage and includes both in- and out-bound deals (with upfront components totalling > $350mio). Markus received his bachelor’s and doctorate degrees in bioengineering from the University of Stuttgart.